GlassScriptPhysician profile
John M Ogrady
NPI 1114911351
$4,081.33
in general payments reported to CMS, 2019-2025
24 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $857 · 2021: $746 · 2022: $604 · 2023: $475 · 2024: $234 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,256.95 | 2019-2025 | Clareon, Unity, Rocklatan |
| Abbvie INC. | $407.06 | 2022-2025 | |
| Allergan, INC. | $261.24 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.34 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $138.39 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $108.82 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $96.09 | 2019-2023 | |
| Genentech USA, INC. | $78.00 | 2022-2025 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $73.84 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $73.60 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $68.43 | 2022-2023 | Vyzulta, Xipere |
| Apellis Pharmaceuticals, INC. | $62.64 | 2023 | Syfovre |
| Alimera Sciences, INC. | $46.07 | 2020 | |
| Astellas Pharma US INC | $44.23 | 2023-2024 | Izervay |
| New World Medical,INC. | $38.60 | 2022-2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $33.56 | 2022-2023 | Tyrvaya |
| Thea Pharma INC. | $22.46 | 2023 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $21.49 | 2023 | Cequa |
| Rayner Intraocular Lenses Limited | $20.00 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Johnson & Johnson Surgical Vision, INC. | $19.99 | 2023 | Tecnis Iol |
| Biotissue Holdings INC. | $18.93 | 2024 | |
| Merz Pharmaceuticals, LLC | $17.58 | 2022 | |
| Beaver-Visitec International, INC. | $15.03 | 2021 | |
| Horizon Therapeutics Plc | $14.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ogrady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.